Clinical Data’s Cogenics Division to Provide Global Genotyping Solutions for Lundbeck’s Clinical Studies

2008-07-15 05:30:00

NEWTON, Mass.–(EMWPresswire)–Clinical Data, Inc. (NASDAQ:CLDA) a leader in the development of

targeted therapeutics and predictive tests from its growing portfolio of

proprietary genetic biomarkers, announced today that its Cogenics®

division has entered into a Scientific Research & Development Agreement

with H. Lundbeck A/S to support its ongoing clinical studies with

genotyping solutions on a global basis. Lundbeck is an international

pharmaceutical company engaged in the research and development,

production, marketing and sale of drugs for the treatment of psychiatric

and neurological disorders.

Under the agreement, Cogenics will employ its clinical genotyping

platforms and expertise based in Morrisville, North Carolina and

Bernried, Germany, to support Lundbecks

clinical studies world-wide, initially focusing on Lundbecks

Phase I studies. The term of the agreement is open-ended and the parties

intend to collaborate on multiple projects going forward.

This agreement with Lundbeck underscores

Cogenics leading position in the clinical

genotyping field, and we are very pleased to form this partnership,

says Michael Lutz, Global General Manager of Cogenics. Having

conducted more than 1700 genotyping studies to support clinical drug

development, we are well positioned to provide value-added genotyping

solutions to Lundbeck on a global basis and in a consistent, high

quality manner.

For more information about Cogenics and its genomic services offerings,

please call 1-877-226-4364 (U.S.) or +49 (0) 8158 – 99 85-0 (E.U.) or

email sales@cogenics.com.

About Cogenics

Cogenics, a division of Clinical Data, has established itself as a

leading provider of value-based genomics solutions for both the

Healthcare and Life Sciences industries. These solutions span the areas

of current and next generation sequencing, gene expression, clinical and

non-clinical genotyping, biomanufacturing support and nucleic acid

extraction and biobanking, for both research and regulated environments.

Cogenics combines operations from the acquisitions of Genaissance

Pharmaceuticals, Lark Technologies (in the US and UK), Icoria, Genome

Express (France) and Epidauros Biotechnologie (Germany). Its customers

include some of the worlds most respected

pharmaceutical and biotechnology companies, agencies of the US National

Institutes of Health, leading government and academic researchers in the

international life science community, and major agricultural companies

and agencies. For more information, please visit www.cogenics.com.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the potential

of molecular discovery, From Targeted Science to Better Healthcare.

Its PGxHealth® division focuses on

proprietary biomarker and pharmacogenetic test development as well as

targeted therapeutics to help predict drug safety and efficacy, thereby

reducing health care costs and improving clinical outcomes. Its Cogenics®

division provides genomics services to both research and regulated

environments. Through these divisions, Clinical Data is leveraging

advances in molecular discovery to provide tangible benefits for

patients, doctors, scientists and health plans worldwide. Visit the

company’s website at www.clda.com for

more information.

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in

the research and development, production, marketing and sale of

pharmaceuticals for the treatment of psychiatric and neurological

disorders. In 2007, the company’s revenue was DKK 11 billion

(approximately EUR 1.6 billion or USD 2.0 billion). The number of

employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM

ACT OF 1995

This press release contains certain forward-looking information and

statements that are intended to be covered by the safe harbor for

forward looking statements provided by the Private Securities Litigation

Reform Act of 1995. Forward-looking statements are statements that are

not historical facts. Words such as “expect(s)”, “feel(s)”,

“believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are

intended to identify forward-looking statements. These statements

include, but are not limited to, statements about our ability to

successfully integrate the operations, business, technology and

intellectual property obtained in our acquisitions; our ability to

obtain regulatory approval for, and successfully introduce our new

products; our ability to expand our long-term business opportunities;

financial projections and estimates and their underlying assumptions;

and statements regarding future performance. All of such information and

statements are subject to certain risks and uncertainties, the effects

of which are difficult to predict and generally beyond the control of

the Company, that could cause actual results to differ materially from

those expressed in, or implied or projected by, the forward-looking

information and statements. These risks and uncertainties include, but

are not limited to, whether Cogenics

services will gain wide acceptance in the market; competition from

pharmaceutical, biotechnology and diagnostics companies; whether

Clinical Data will be able to develop or acquire additional products and

attract new business and strategic partners; changes in government

regulations, and changing relationships with customers, payers,

suppliers and strategic partners; and those risks identified and

discussed by Clinical Data in its filings with the U.S. Securities and

Exchange Commission. Readers are cautioned not to place undue reliance

on these forward looking statements that speak only as of the date

hereof. Clinical Data does not undertake any obligation to

republish revised forward-looking statements to reflect events or

circumstances after the date hereof or to reflect the occurrence of

unanticipated events. Readers are also urged to carefully review and

consider the various disclosures in Clinical Data’s SEC periodic and

interim reports, including but not limited to its Annual Report on Form

10-K for the fiscal year ended March 31, 2008, and Current Reports on

Form 8-K filed from time to time by the Company.

EVC Group, Inc. for Clinical Data, Inc.
Matthew Selinger,

+1-415-896-6817 (investors)
Steve DiMattia, +1-646-201-5445 (media)
Chris

Gale, +1-646-201-5431 (media)

free cash grants, free grant money, free money, cash grants, scholarships, business grants, foundation grants, government grants, debt grants, consolidation, college tuition, financial aid, medical grants, personal grants, medical bills, unsecured loans, no interest loans, financing, loans, capital, non profit organizations

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions